Treatment Options: Standard Care and New Frontiers

The first goal of treatment for Familial Focal Epilepsy with Variable Foci 1 (FFEVF1) is to achieve seizure freedom using anti-seizure medications (ASMs). Because this is a focal-onset epilepsy, doctors typically choose medications that are effective at stabilizing the electrical activity in specific areas of the brain.

There is no single “best” medication uniquely preferred just because a person carries a DEPDC5 variant ^[1]. Instead, your doctor will select a drug based on your age, the specific type of seizures you have, reproductive plans, and other health factors ^[1]. Common choices include:

• Sodium-Channel Blockers: Medications like carbamazepine, oxcarbazepine, or lacosamide are often used for focal seizures. Some studies of families with similar genetic mutations have shown good responses to these drugs ^[2][3].
• Broad-Spectrum Options: Medications like levetiracetam or lamotrigine may also be prescribed ^[4][5].

Every medication has potential side effects. Lamotrigine requires a slow dose-titration due to rash risk, and levetiracetam can cause mood changes. Never change or stop a medication without your prescriber’s guidance.

Understanding Drug-Resistant Epilepsy

For many families, the first or second medication tried works well. However, FFEVF1 is known for being “variable” not just in its symptoms, but also in how it responds to treatment.

Medical professionals use a specific definition for drug-resistant epilepsy (DRE): it is the failure to achieve sustained seizure freedom after trying two appropriately chosen and tolerated ASMs ^[6].

• The Reality of FFEVF1: Research suggests that drug resistance is common in this condition. Estimates vary, but some pooled reviews of specialty clinic cohorts show that nearly 48% of these affected individuals may eventually meet the criteria for drug-resistant epilepsy ^[7][8].
• Risk Factors: Children who have their first seizure before age one, or those who have developmental delays, may be at a higher risk for seizures that are difficult to control with medication alone ^[7][9].

If you or your child reach this “two-medication” threshold, it is standard practice to be referred to a comprehensive epilepsy center for a more specialized evaluation, which involves a multidisciplinary review ^[6].

Precision Medicine: The mTOR Pathway

Because we know that DEPDC5 mutations cause the mTOR pathway (the brain’s growth engine) to run too fast, scientists are investigating “precision” treatments that target this specific biological problem ^[10][11].

mTOR Inhibitors (such as everolimus) are drugs that act directly on this pathway.

• Current Status: These drugs are already FDA-approved for a different genetic condition called Tuberous Sclerosis Complex (TSC) ^[11]. However, they are investigational and off-label for FFEVF1 ^[12].
• Early Evidence: Very small, preliminary case reports have shown that some people with drug-resistant DEPDC5 epilepsy had a significant reduction in seizures when adding everolimus to their treatment ^[12][13].
• Side Effects and Risks: These are powerful medications that can cause mouth sores (stomatitis), increased risk of infections, and changes in cholesterol or mood ^[12][14].

Because the evidence is still in the early stages, everolimus is not a standard treatment. A trial of these drugs should not delay an evaluation for potentially effective epilepsy surgery ^[11][13].

Other Treatment Options

When medications aren’t enough, other proven therapies may be considered by a specialist:

• Ketogenic Diet: A specialized high-fat, low-carbohydrate medical diet has shown initial success in reducing seizures for some children with DEPDC5 mutations, though it requires strict medical supervision ^[15].
• Epilepsy Surgery: For those with a clear “focus”, surgery can be highly effective after multidisciplinary review ^[7].